A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

Valeria Merz,Camilla Zecchetto,Francesca Simionato,Alessandro Cavaliere,Simona Casalino,Michele Pavarana,Simone Giacopuzzi,Maria Bencivenga,Anna Tomezzoli,Raffaela Santoro,Vita Fedele,Serena Contarelli,Irene Rossi,Serena Giacomazzi,Martina Pasquato,Cristiana Piazzola,Stefano Milleri,Giovanni De Manzoni,Davide Melisi

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

2020

Valeria Merz
Camilla Zecchetto
Francesca Simionato
Alessandro Cavaliere
Simona Casalino
Michele Pavarana
Simone Giacopuzzi
Maria Bencivenga
Anna Tomezzoli
Raffaela Santoro
Vita Fedele
Serena Contarelli
Irene Rossi
Serena Giacomazzi
Martina Pasquato
Cristiana Piazzola
Stefano Milleri
Giovanni De Manzoni
Davide Melisi

Background:Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted ...

Keywords:

trastuzumab resistance
Fibroblast growth factor receptor
Medicine
in patient
Cancer
Pathology
Cancer research
Trastuzumab
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations